HPP854 / vTv Therapeutics - LARVOL DELTA

Safety study of HPP854 in subjects with mild cognitive impairment or a diagnosis of mild Alzheimer's disease (clinicaltrials.gov) - P1, N=7; Sponsor: High Point Pharmaceuticals; N=30 -> 7; Recruiting -> Terminated

Enrollment change • Trial termination • Alzheimer's Disease